Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by Steve33on Jun 07, 2021 9:00am
97 Views
Post# 33339061

RE:RE:RE:PreMarket $5.62 thus far

RE:RE:RE:PreMarket $5.62 thus far
That is a possibility but we should be between 20 to 30 dollars with our first BLA and PRV or maybe more. There should have been no deal with Kedrion. We could have kept our blood business and made plasminogen and IVIG at 100 million plus a year. Then added more proteins and the sky is the limit. FDA wouldn't have to approve each new protein and we would be off to the moon. Thompson would make insane amounts of money. It just seems way easier and more lucrative than what you suggest. But who really knows.
<< Previous
Bullboard Posts
Next >>